Belite Bio, Inc. Sponsored ADR

BLTE Healthcare Biotechnology

EPS
−40.0%
Free cash flow
+64.7%

Quarter to June 2026, against a year earlier

154.46 11.27 +7.87%
Market cap
$5.8B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Belite Bio, Inc. Sponsored ADR (BLTE) Book value per share

Alert me on Book value per share

Belite Bio, Inc. Sponsored ADR's book value per share at the end of fiscal 2025 was 23.0×, up 381.1% from 4.8× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 19.3×. Over the past ten years it has ranged from −1.6× (fiscal 2021) to 23.0× (fiscal 2025) — the current reading is the highest in ten years. Belite Bio, Inc. Sponsored ADR ranks 36th of 611 Biotechnology companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 23.0× 381.11%
FY2024 4.8× 40.43%
FY2023 3.4× 63.69%
FY2022 2.1× —
FY2021 −1.6× —
FY2020 −0.8× —

Quarterly newest first

Period Book value per share Change
Jun 2026 19.3× (3.17%)
Mar 2026 20.0× (13.12%)
Dec 2025 23.0× 178.47%
Sep 2025 8.2× 79.35%
15 more quarters

Against its own ten years

Low −1.6× High 23.0×
Ten-year median 2.7×
Current reading's percentile 100

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on BLTE